Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Launched by FOREST LABORATORIES · Apr 29, 2008
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presence of COPD as defined by GOLD criteria (2006); post-bronchodilator FEV1/FVC \<70%, and post-bronchodilator FEV1 \>30% and \< 80% predicted
- • Current or former cigarette smoker
- Exclusion Criteria:
- • Long-term oxygen use of \> 15 hours a day
- • Symptoms consistent with a significant asthmatic component (e.g. atopic disease, allergic symptoms)
- • Any COPD exacerbations within 30 days prior to study entry or during run-in
- • History of chronic or recurrent gastrointestinal disorder associated with bleeding in previous 12 months
- • Presence of clinical significant pulmonary disease other than COPD
About Forest Laboratories
Forest Laboratories, a subsidiary of Allergan, is a leading global pharmaceutical company dedicated to the development and commercialization of innovative therapies that address unmet medical needs. With a strong focus on central nervous system disorders, including depression and anxiety, as well as other therapeutic areas, Forest Laboratories emphasizes rigorous clinical research and development to ensure the safety and efficacy of its products. The organization is committed to advancing healthcare through scientific excellence, collaboration, and a patient-centered approach, aiming to enhance the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ormond Beach, Florida, United States
Tamarac, Florida, United States
Evansville, Indiana, United States
North Dartmouth, Massachusetts, United States
Cherry Hill, New Jersey, United States
Rochester, New York, United States
Medford, Oregon, United States
Phoenix, Arizona, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Charleston, South Carolina, United States
San Antonio, Texas, United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Buena Park, California, United States
Encinitas, California, United States
Fullerton, California, United States
Los Angeles, California, United States
Orange, California, United States
Rancho Mirage, California, United States
San Diego, California, United States
Stockton, California, United States
Centennial, Colorado, United States
Wheat Ridge, Colorado, United States
Wheat Ridge, Colorado, United States
Waterbury, Connecticut, United States
Fort Lauderdale, Florida, United States
Miami, Florida, United States
Skokie, Illinois, United States
Livonia, Michigan, United States
Edina, Minnesota, United States
Minneapolis, Minnesota, United States
Papillion, Nebraska, United States
Cherry Hill, New Jersey, United States
Elmira, New York, United States
Mineola, New York, United States
Charlotte, North Carolina, United States
Cincinnati, Ohio, United States
Toledo, Ohio, United States
Portland, Oregon, United States
Bethlehem, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Charleston, South Carolina, United States
Greenville, South Carolina, United States
Spartanburg, South Carolina, United States
El Paso, Texas, United States
Fredericksburg, Virginia, United States
Tacoma, Washington, United States
Patients applied
Trial Officials
Brian T Maurer, MS
Study Director
Forest Laboratories
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials